Microbiome gets skinny

How Xycrobe is harnessing the skin microbiome to deliver dermal therapies


While other microbiome companies battle intestinal diseases with cocktails of gut bacteria or bacteria-derived compounds, Xycrobe Therapeutics Inc. is moving beyond the gut with a platform that harnesses commensal bacteria in skin for continuous, local delivery of therapies for acne, psoriasis and other dermal diseases.

Xycrobe’s platform engineers bacteria to produce therapeutic compounds, using two species that occur naturally in the skin: Propionibacterium

Read the full 639 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE